Strategies for Developing Biomarkers of Heart Failure

Strategies for developing biomarkers of heart failure.

BACKGROUND Heart failure (HF) is a devastating disease with increasing prevalence in elderly populations. One-half of all patients die within 5 years of diagnosis. The annual cost of treating patients with HF in the US is more than $20 billion, which is estimated to be greater than that of myocardial infarction and all cancers combined. Given the complex pathophysiology and varied manifestation...

Biomarkers in heart failure.

Nowadays, heart failure (HF) has an increasing prevalence, particularly in the elderly, and is becoming a clinical problem of epidemic proportion in terms of morbidity and mortality. Developing biological markers, that can aid in the diagnosis of HF and in the differentiation of congestive heart failure (CHF) from other causes of dyspnoea, will reduce the cost of health care. However, an ideal ...

Biomarkers in heart failure.

http://heart.bmj.com/content/96/4/314.full.html Updated information and services can be found at: These include: References http://heart.bmj.com/content/96/4/314.full.html#ref-list-1 This article cites 23 articles, 14 of which can be accessed free at: service Email alerting box at the top right corner of the online article. Receive free email alerts when new articles cite this article. Sign up ...

Biomarkers in heart failure.

Copyright © 2008 Massachusetts Medical Society. Heart failure, a major and growing public health problem, appears to result not only from cardiac overload or injury but also from a complex interplay among genetic, neurohormonal, inflammatory, and biochemical changes acting on cardiac myocytes, the cardiac interstitium, or both. An increasing number of enzymes, hormones, biologic substances, and...

Biomarkers in heart failure: ready for use?